Dejerine–Roussy syndrome

Lineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord Injury

Retrieved on: 
Monday, February 8, 2021
Research, General Health, Medical devices, Genetics, Clinical trials, Science, Surgery, Biotechnology, Stem cells, FDA, Other Science, Health, Nervous system, Organ systems, Pain, Acute pain, Nociception, Neuropathic pain, Spasticity, Dejerine–Roussy syndrome, Myelomalacia, Spinal Cord Injuries, OPC1, the OPC1 Clinical Study, Neurgain Technologies, Inc., Lineage Cell Therapeutics, Inc.

If results from the PDI system are positive, then Lineage may exercise its option to enter into a pre-negotiated license and commercialization agreement with Neurgain.

Key Points: 
  • If results from the PDI system are positive, then Lineage may exercise its option to enter into a pre-negotiated license and commercialization agreement with Neurgain.
  • Pursuant to that agreement, Lineage may integrate the PDI system into a later-stage clinical trial and if approved, commercial use of OPC1 for the treatment of patients with a cervical spinal cord injury.
  • There currently are no U.S. Food and Drug Administration (FDA) approved treatments for spinal cord injury.
  • Neurgain is developing a novel gene therapy technology and delivery devices to treat chronic neuropathic pain and spinal spasticity.

Novel Treatment Provides New Hope for Relief of Disabling Stroke Pain - Institute of Neurological Recovery

Retrieved on: 
Wednesday, October 23, 2019
Pain, Perception, Organ systems, Acute pain, Nociception, Palliative care, Dejerine–Roussy syndrome, Thalamus, Pain management, Central pain syndrome, Stroke, Chronic pain

The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.

Key Points: 
  • The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.
  • Central pain, pain due to injury of neuronal tissue, was first described after stroke in 1906.
  • Previously referred to as thalamic pain, now as central post-stroke pain, it is characteristically chronic, disabling and resistant to all treatment.
  • "This novel treatment provides new hope for the many people who have survived stroke only to find themselves left with agonizing daily pain that does not respond to any treatment," said Dr. Tobinick.

Novel Treatment Provides New Hope for Relief of Disabling Stroke Pain - Institute of Neurological Recovery

Retrieved on: 
Wednesday, October 23, 2019
Pain, Perception, Organ systems, Acute pain, Nociception, Palliative care, Dejerine–Roussy syndrome, Thalamus, Pain management, Central pain syndrome, Stroke, Chronic pain

The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.

Key Points: 
  • The publications report rapid and sustained pain relief using a novel method of drug delivery, perispinal administration1, to accomplish effective brain delivery and relief of central pain, without surgery.
  • Central pain, pain due to injury of neuronal tissue, was first described after stroke in 1906.
  • Previously referred to as thalamic pain, now as central post-stroke pain, it is characteristically chronic, disabling and resistant to all treatment.
  • "This novel treatment provides new hope for the many people who have survived stroke only to find themselves left with agonizing daily pain that does not respond to any treatment," said Dr. Tobinick.